References of "Dresse, Marie-Françoise"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDifferential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials
Piette, Caroline ULiege; Suciu, S; Clappier, E et al

in Leukemia : Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K (2017)

In childhood B-cell precursor acute lymphoblastic leukaemias (BCP-ALL), the presence of an ETV6-RUNX1 fusion transcript defines one of the most prevalent genetic subgroups, together with the high ... [more ▼]

In childhood B-cell precursor acute lymphoblastic leukaemias (BCP-ALL), the presence of an ETV6-RUNX1 fusion transcript defines one of the most prevalent genetic subgroups, together with the high hyperdiploidy (HeH) ALL. Although ETV6-RUNX1pos ALLs are associated with favourable outcome, their proper treatment strategies remain debatable, some groups suggesting crucial impact of upfront intensive treatment while others favour low-intensity antimetabolite-based therapy. [less ▲]

Detailed reference viewed: 26 (2 ULiège)
Full Text
Peer Reviewed
See detailEffect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial
Sins, JWR; Fijnvandraat, K; Rijneveld, AW et al

in British Journal of Haematology (2017)

Detailed reference viewed: 11 (2 ULiège)
Full Text
Peer Reviewed
See detailMetronomic treatments in Pediatric Neuro-Oncology, a new therapeutic alternative?
Fohn, Anaïs; Hoyoux, Claire; DRESSE, Marie-Françoise ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2017, March), 19(1), 88

Detailed reference viewed: 16 (1 ULiège)
Full Text
Peer Reviewed
See detailNeonatal screening improves sickle cell disease clinical outcome in Belgium.
Lê, Phu-Quoc; Ferster, A; Dedeken, L et al

in Journal of Medical Screening (2017)

Objectives To compare the outcomes of sickle cell disease patients diagnosed through neonatal screening with those who were not. Methods In an observational multicenter study in Belgium, 167 screened and ... [more ▼]

Objectives To compare the outcomes of sickle cell disease patients diagnosed through neonatal screening with those who were not. Methods In an observational multicenter study in Belgium, 167 screened and 93 unscreened sickle cell disease patients were analyzed for a total of 1116 and 958 patient-years of follow-up, respectively. Both groups were compared with propensity score analysis, with patients matched on three covariates (gender, genotype, and central Africa origin). Bonferroni correction was applied for all comparisons. Results Kaplan-Meier estimates of survival without bacteremia were significantly higher in the screened group than the unscreened group (94.47%; [95% CI, 88.64-97.36%] versus 83.78% [95% CI, 72.27-90.42%]), p = 0.032. Non-significant differences between both groups were reported for survival without acute chest syndrome, acute anemia, cerebral complication, severe infection, and vaso-occlusive crisis. Significantly lower hospitalization rate and days per 100 patient-years were observed in the screened compared with the unscreened group (0.27 vs. 0.63 and 1.25 vs. 2.82, p = 0.0006 and <0.0001). Conclusion These data confirm the benefit of a neonatal screening programme in reducing bacteremia and hospitalization. [less ▲]

Detailed reference viewed: 13 (0 ULiège)
Full Text
Peer Reviewed
See detailLong Term Socioeconomic Outcomes of Childhood Acute Lymphoblastic Leukemia (ALL) Survivors Enrolled in EORTC Children Leukemia Group Trials 58741, 58831/2 and 58881
Barbati, Mélissa; Kicinski, Michal; Suciu, Stefan et al

in Blood (2017)

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailNewborn screening for sickle cell disease : 13 years at the CHR "La Citadelle", Liège
Sepulchre, Edith; Ketelslegers, Olivier; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016, March), 18(1), 107

Detailed reference viewed: 23 (1 ULiège)
Full Text
See detailContraception hormonale chez l'adolescente avec thrombophilie biologique
Minon, Jean-Marc; Vasbien, Myriam; DRESSE, Marie-Françoise ULiege et al

in Belgian Journal of Paediatrics (2016), 18(2), 173-176

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the ... [more ▼]

Venous thromboembolism among pill users is rare but is a serious complication. Women with inherited thrombophilia are at increased risk when taking combined oral contraceptives. It is also truth for the contraceptive patch and vaginal ring. Hence, the adolescents with a know biological thrombophilia should not take htis type of hormonal conraception. However, some of these thrombophilia should not preclude use of estrogen containing contraception. Actually, if thrombophilia testing can be justified in asymptomtic patient at high risk, it is sometimes performed as screening in adolescent before estrogen-containnig contraception use ( non recommended). In these situations and considering the venous thrombosis as a multicausal disease, the choice of contraceptive methods is argued on the base of family history and other personnal risk factors of venous thrombosis. [less ▲]

Detailed reference viewed: 74 (2 ULiège)
Full Text
Peer Reviewed
See detailPurpura thrombocytopénique idiopathique...idiopathique, vraiment?
LONGTON, Julie ULiege; DRESSE, Marie-Françoise ULiege; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2016), 18(1), 112

Detailed reference viewed: 21 (2 ULiège)
Full Text
Peer Reviewed
See detailTumeurs rhabdoïdes néonatales : à propos de deux cas.
Carichon, T; FORGET, Patricia ULiege; Piette, Caroline ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 22 (2 ULiège)
Full Text
Peer Reviewed
See detailPosterior Reversible Encephalopathy Syndrome in Pediatric Leukemia
Carichon, Tifenn ULiege; Piette, Caroline ULiege; Florkin, Benoît et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 48

Detailed reference viewed: 18 (2 ULiège)
Full Text
Peer Reviewed
See detailSplénomégalie palustre hyperimmune et drépanocytose. A propos d'un cas
Lefevre, Annabelle; Hoyoux, Marie; DRESSE, Marie-Françoise ULiege

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1),

Detailed reference viewed: 11 (2 ULiège)
Full Text
Peer Reviewed
See detailL'impact d'un programme régulier d'Erythrocytaphérèse sur les complications de la drépanocytose
DRESSE, Marie-Françoise ULiege; Hoyoux, Marie; Ketelslegers, Olivier et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 82

Detailed reference viewed: 24 (2 ULiège)
Full Text
Peer Reviewed
See detailDescription and Management of Accelerated Phase and Blast Crisis in 21 CML Pediatric Patients
Meyran, Deborah; Petit, Arnaud; Guilhot, Joelle et al

Poster (2015)

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency ... [more ▼]

Philadelphia-positive chronic myelogenous leukemia (CML) is a rare disease in children and constitutes approximately 3-5% of all childhood leukemias. With tyrosine kinase inhibitors (TKI), the frequency of accelerated phase (AP) or blast crisis (BC) is remarkably reduced, estimated to 1% to 1.5% per year in adults compared with more than 20% per year in the pre-TKI era. But no data are available among children. Purpose: We described the characteristics, the treatment and the outcome of 21 children with CML, who evolved in accelerated phase and/or blast crisis under TKI. Results: From 2001 to april 2015, 415 European patients were enrolled in the CML pediatric database. Twenty-one patients (5.1%), in chronic phase (CP) treated by TKI, presented AP or BC. The median age of AP /BC cohort was 13.2 years (range: 4.5-16.9 years) with a sex ratio M/F at 2. At CML diagnosis, 15 patients (71%) had high risk Sokal Score with a median score of 1,4 (range: 0,16-2,4). All patients harbored t(9;22)(q34;q11) but one had a complex translocation t(1;9;22)(q12;q34;q11) and another one presented additional inv(3)(q21q26). Imatinib was the first line TKI for all patients. Before AP or BC, only five patients (24%) obtained a complete cytogenetic response (CCyR) and three achieved MMR. For incomplete molecular response or progression to accelerated phase, 8 patients (38%) were switched to dasatinib. Median duration of TKI before AP or BC was 11 months (range: 3 months-56.5 months). Six patients evolved to AP with a median interval of 8.7 months (range: 1 months-24 months), leading to blast crisis for 4 patients with a median time of 3.5 months (range: 0.3-5.4 months). Among the 2 patients remaining in AP, imatinib was increased for one and the other was switched for dasatinib, all before hematopoietic stem cells transplantation (HSCT). One patient died of post-transplant complication and the other one is still alive in complete molecular response without TKI. Nineteen patients presented BC, including 4 after AP. Thirteen patients (62%) presented ALL, five (24%) AML and one a bi phenotypic leukemia. Central nervous system (CNS) was involved for two patients with ALL, one isolated, one combined. At AP or BC, nine patients (43%) presented new additional cytogenetic abnormalities. Eighteen patients with BC were treated according to AML or ALL protocols, combined with second generation TKI for twelve patients. Only one patient underwent preparative regimen, without intensive chemotherapy before HSCT. Ten patients reached complete remission. Four patients died before HSCT, by progressive disease for 2 and by fatal infection for 2. Overall, 15 patients in BC were transplanted. Before HSCT, median molecular response was 0.2% (range: 0-29%) and only four patients had a complete molecular response. After transplant, seven patients received second generation TKI. Four patients died, including three related to transplant toxicity. Thirteen patients were alive, but one with ALL BC relapsed 26 months post-transplant and was waiting for second HSCT. With a median follow-up of 4.4 years, 4-year overall survival was 59% (66% for ALL BC versus 40% for AML BC). Conclusion: Incidence of AP/BC after imatinib for CP CML is at 5%, in the CML pediatric database. Despite second generation TKI, combined with HSCT, outcome remains poor. Post-transplant indication of TKI is heterogenic. Recommendations would be useful for practice. [less ▲]

Detailed reference viewed: 28 (2 ULiège)
Full Text
Peer Reviewed
See detailSchizencephaly associated with a severe prothrombotic syndrome caused by antithombin III deficiency
Daron, Aurore; DRESSE, Marie-Françoise ULiege; Hoyoux, Claire ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 109

Detailed reference viewed: 23 (4 ULiège)
Full Text
Peer Reviewed
See detailDécrochage de la courbe de périmètre crânien et si l’origine n'était pas neurologique
LONGTON, Julie ULiege; DRESSE, Marie-Françoise ULiege; Hoyoux, Marie et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 15 (4 ULiège)
Full Text
Peer Reviewed
See detailUNE TUMEUR RARE DE LA FACE CHEZ UN NOURRISSON DE 6 MOIS
Fontaine, C; DEMEZ, Pierre ULiege; FORGET, Patricia ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 46

Detailed reference viewed: 40 (6 ULiège)
Full Text
Peer Reviewed
See detailLE CANCER DU TRES JEUNE ENFANT : EPIDEMIOLOGIE LIEGEOISE
Fontaine, C; RIGO, Vincent ULiege; FORGET, Patricia ULiege et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 47

Detailed reference viewed: 20 (2 ULiège)
Full Text
Peer Reviewed
See detailUTILISATION D'UNE FISTULE ARTERIO-VEINEUSE CHEZ DES PATIENTS DREPANOCYTAIRES SOUS ERYTHROCYTAPHERESE
Hoyoux, Marie; DRESSE, Marie-Françoise ULiege; Minon, Jean-Marc et al

in Tijdschrift van de Belgische Kinderarts = Journal du Pédiatre Belge (2015), 17(1), 49

Detailed reference viewed: 25 (1 ULiège)
Full Text
Peer Reviewed
See detailSurvival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment
Lê, Phu Quoc; Gulbis, Béatrice; Dedeken, Laurence et al

in Pediatric Blood & Cancer (2015), 62

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry ... [more ▼]

Objective. To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method. The Registry created in 2008 included patients of eight centers. All available data in 2008 were retrospectively encoded in the database. After 2008 and until 2012, all data were recorded prospectively for already registered patients as well as newly diagnosed subjects. Data were registered from neonatal screening or from diagnosis (first contact) until last follow-up or death. Data included diagnosis, demography, and outcome data. Results. We collected data from 469 patients over a 5,110 patient years (PY) follow-up period. The global mortality rate was low (0.25/100 PY), although 13 patients died (2.8%) and was similar between children, adolescents (10–18 years), and young adults (P¼0.76). Out of the cohort, 185 patients received hydroxyurea at last follow-up (median duration of treatment: 10.3 years), 90 underwent hematopoietic stem cell transplantation (HSCT), 24 were chronically transfused, and 170 had never had any DMT. Hydroxyurea showed significant benefit on patients outcome as reflected by a lower mortality rate compared to transplanted individuals or people without DMT (0.14, 0.36, and 0.38 per 100 PY, respectively) and by higher Kaplan–Meier estimates of 15 year survival (99.4%) compared to HSCT (93.8%; P¼0.01) or no DMT groups (95.4%; P¼0.04). Conclusion. SCD mortality in Belgium is low with no increase observed in young adults. Patients treated with hydroxyurea demonstrate a significant benefit in survival when compared to those withoutDMTor transplanted. [less ▲]

Detailed reference viewed: 73 (3 ULiège)